Gossamer Bio is trading 6.1% down at $10.00 in pre-market, with no clear company-specific overnight catalyst identified.
- Shares declined 0.56% at the October 5 close.
- The latest prominent company news was its September 2026 NDA submission for seralutinib; available search results showed no new October 6 announcement explaining the decline.
- Major U.S. indices were modestly higher in the supplied market context, which does not clearly explain the drop.